Inhibitor Screening Kits

Background

Immune checkpoint pathway is a focal point of today's cancer research. PD-1 is one of the best characterized checkpoint proteins. The binding between PD-1 and its ligand PD-L1 suppresses T-cell activation and allows cancer cells to escape from body's immune surveillance. Therefore, neutralizing PD-1 pathway activity has been considered a promising strategy by many oncologists.

This inhibitor screening ELISA pair is designed to facilitate the identification and characterization of new PD-1 pathway inhibitors. This assay employs a simple colorimetric ELISA platform, which measures the binding between immobilized human PD-L1 and in-house developed biotinylated PD-1 protein. This product is uniquely suitable for rapid high-throughput screening of putative PD-1 and PD-L1 inhibitors.

                                                                                                                       

Assay Principle

Your experiment will include 4 simple steps:        a) coat the plate with human PD-L1,        b) add biotinylated human PD-1 to bind with PD-L1, and        c) add your molecule of interest to the reactions,        d) add Streptavidin-HRP followed by TMB or other colorimetric HRP substrate to measure the binding activities. The ability of your compound to inhibit PD-1 : PD-L1 binding will be determined by comparing OD readings among different experimental groups.

Immobilized human PD-L1 protein (Cat. No. A001-214) at 2 μg/mL (100 μL/well) can bind biotinylated human PD-1 (Cat. No. A002-214) with a linear range of 0.038 - 0.6 μg/mL when detected by Streptavidin-HRP (Cat. No. A003-214).

Inhibition of PD-1-PD-L1 binding by Anti-PD-1 neutralizing antibody (Cat. No. PD1-NA001) measured using the PD-1 [Biotinylated] : PD-L1 Inhibitor Screening ELISA Assay Pair (Cat. No. EP-101).

Product List

Product Highlights

By employing the pre-labeled PD-1 protein, we eliminate the often time-consuming labeling process, and greatly simplify the experimental procedures.

Both biotinylated PD-1 and PD-L1 proteins are expressed in the HEK293 cells. The use of human cells as expression host confers authentic post-translational modifications essential for their binding activities.

We include anti-PD1 neutralizing mAb as a standard positive control. This would allow the users to validate their experiments.

We offer both 96 tests and 480 tests as standard package sizes, which enables simultaneous analyses of a large amount of inhibitors.

Our biotin labeling platform produces biotinylated proteins with high detection sensitivity and minimal lot-to-lot variation. These features ensure that the assay kit has desired detection sensitivity and the results are reproducible.